Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Meiragtx Holdings Plc (NQ: MGTX )

8.350 -0.030 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 156,792
Open 8.480
Bid (Size) 3.360 (1)
Ask (Size) 10.05 (4)
Prev. Close 8.380
Today's Range 8.270 - 8.668
52wk Range 5.695 - 15.87
Shares Outstanding 44,725,678
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms
 
Via Benzinga
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via Globe NewsWire

Performance

YTD
+28.86%
+28.86%
1 Month
+28.86%
+28.86%
3 Month
+19.80%
+19.80%
6 Month
-15.91%
-15.91%
1 Year
-40.44%
-40.44%

More News

Read More
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
From MeiraGTx
Via Globe NewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via Globe NewsWire
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial
Via Benzinga
MeiraGTx Hldgs: Q1 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
From MeiraGTx
Via Globe NewsWire
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
From MeiraGTx
Via Globe NewsWire
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
From MeiraGTx
Via Globe NewsWire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Via Benzinga
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
Via Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
46 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
Via Benzinga
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.